Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SAN DIEGO, May 8, 2013 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced the pricing of its initial public offering of 5,200,000 shares of its common stock at an initial public offering price of $14.00 per share. The shares of Receptos’ common stock are expected to begin trading on the Nasdaq Global Market under the symbol “RCPT” on May 9, 2013. All of the shares of common stock are being offered by Receptos. In addition, Receptos has granted the underwriters a 30-day option to purchase up to an additional 780,000 shares of common stock to cover over-allotments, if any. The offering is expected to close on May 14, 2013, subject to customary closing conditions.
Help employers find you! Check out all the jobs and post your resume.
